ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of the Prostate (PCS VI) – UroToday

1. ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of the Prostate (PCS VI)  UroToday
2. Adding PSMA-targeting radioligand therapy to stereotactic body radiotherapy more than doubled progression-free survival in men with recurrent prostate cancer  UCLA Health
3. ASTRO 2025: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial  UroToday
4. ASTRO: Targeted Radioactive Therapy, New SBRT Approaches, 5DCT-Guided Imaging and More  Oncodaily
5. Radiopharmaceutical added to stereotactic radiation can delay prostate cancer progression  Medical Xpress

Continue Reading